A recent study found that toxicity is routinely minimized in phase 3 oncology trials, especially those that are not industry sponsored.
Although participants in the study had greater rates of nonadherence postintervention, those who reported nonadherence at ...
Staying up to date with data from trials and information from organizations dedicated to cancer research is crucial for ...
And again, it's very important that we educate the population. And when nurses are educated on the different subtypes of breast cancer, then we can also—we feel empowered. And now we can empower the ...
One of the hardest lessons learned occurred after I inadvertently failed at communication and education before transferring a ...
The FDA has accepted the resubmission of a BLA for odronextamab for the treatment of patients with relapsed/refractory ...
Cilta-Cel Associated With Higher HRQOL for Lenalidomide-Refractory MM ...
The FDA has granted PYX-201 fast track designation for treatment of recurrent or metastatic HNSCC after progression post-chemoimmunotherapy. PYX-201 received FDA fast track designation for use in ...
Cilta-Cel Associated With Higher HRQOL for Lenalidomide-Refractory MM ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback